Previous FY23 revenue excluding ELAHERE was $30M-$35M. Sees FY23 operating expenses $320M-$335M. ImmunoGen expects to provide ELAHERE product revenue guidance later this year. The increase in revenue guidance is a result of recognizing a $15M upfront fee from Vertex in the first quarter as no deferral was required. Additionally, the Company increased its operating expense guidance to reflect greater spend in support of ELAHERE’s launch and expected growth trajectory. ImmunoGen expects that its current cash, inclusive of the $75M received pursuant to the term loan facility with Pharmakon, and combined with anticipated product and collaboration revenues, will fund operations into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- ImmunoGen Rockets Up on Great Sales, Earnings
- ImmunoGen names Isabel Kalofonos as Chief Commercial Officer
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Sutro transferred with Equal Weight from Overweight at Wells Fargo
- Immunogen confident in early Elahere launch, says Guggenheim